Lipids & metabolic liver disease
Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study
Authors' conclusion
Obesity and non-obesity MASLD phenotypes were predictors of all-cause mortality following AMI, with an even larger magnitude of mortality risk in the non-obesity MASLD group. The recognition of MASLD and its body weight phenotypes will be beneficial in the prognostication following AMI.
Study context
- Population
- Patients with acute MI (acute myocardial infarction (AMI)) in a secondary preventative cohort, stratified by MASLD and obesity
- Participants
- 5,702 patients
- Exposure
- MASLD and body weight phenotypes after AMI
- Outcome
- All-cause mortality
- Follow-up
- Long-term
Main finding
As reported in the abstract
Long-term all-cause mortality
Hazard ratio (95% CI)P value
Non-obesity MASLD
1.400(1.077–1.820)
P = 0.012Obesity MASLD
1.222(1.005–1.485)
P = 0.044- Non-obesity MASLD had the highest risk of all-cause long-term mortality
- P = 0.019
Observational data: associations, not effects.
Further findings
Heart failure
- Highest risk with non-obesity MASLD
- P = 0.034
Cardiogenic shock
- Highest risk with non-obesity MASLD
- P < 0.001
Cardiometabolic burden
- Highest in obesity MASLD, followed by non-obesity MASLD
Original publication
Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study. Diabetes Obes Metab. Published 11 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →